

National Audit of Metastatic Breast Cancer State of the Nation Report 2026: Methodology Supplement

An audit of care received by people diagnosed with metastatic breast cancer between 1 January 2021 and 31 December 2023 in England and Wales.

Published September 2026



Citation for this document:

National Audit of Metastatic Breast Cancer (NAoMe) State of the Nation Report 2026. London:
National Cancer Audit Collaborating Centre, Royal College of Surgeons of England, 2026.

This document was prepared by members of the NAoMe project team:

Kieran Horgan, Surgical Lead
David Dodwell, Clinical Oncology Lead
Mark Verrill, Medical Oncology Lead
Georgina Hanbury, Clinical Research Fellow
Sarah Blacker, Clinical Research Fellow
Jemma Boyle, Senior Clinical Research Fellow
Liyang Wang, Clinical Research Fellow
Christine Delon, Data Scientist
Diana Withrow, Methodologist

David Cromwell, Senior Methodologist
Robert Douce, Programme Manager

With review and input from:

[NAoMe Audit Advisory Committee \(Clinical Reference Group\)](#)
[NATCAN Executive Team](#)



The Royal College of Surgeons of England is an independent professional body committed to enabling surgeons to achieve and maintain the highest standards of surgical practice and patient care. As part of this it supports audit and the evaluation of clinical effectiveness for surgery. Registered Charity no: 212808.



The National Cancer Audit Collaborating Centre (NATCAN) is commissioned by the [Healthcare Quality Improvement Partnership \(HQIP\)](#) and funded by NHS England and Welsh Government as part of the [National Clinical Audit and Patient Outcomes Programme \(NCAPOP\)](#). NATCAN delivers national audits in bowel, breast (primary and metastatic), kidney, lung, non-Hodgkin lymphoma, oesophago-gastric, ovarian, pancreatic and prostate cancers.



The Association of Breast Surgery is a registered charity dedicated to advancing the practice of breast surgery and the management of breast conditions for the benefit of the public. It is a multi-professional membership association, which promotes training, education, clinical trials and guideline composition and adoption. For further information, please refer to the website www.associationofbreastsurgery.org.uk. Registered charity no: 1135699



The UK Breast Cancer Group (UKBCG) is a forum for Clinical and Medical Oncologists. The UKBCG acts as a stakeholder to NICE, NHS England and other organisations; and undertakes key pieces of work, at times in collaboration with other bodies, with the overriding endpoint of improving patient care. The Group's objectives include advancing the education of clinical and medical oncologists in the subject of breast cancer, concerning its identification, diagnosis and treatment; promoting research for the public benefit in all aspects of breast cancer and publishing the results; and assisting in the treatment and care of persons suffering from breast cancer, or in need of rehabilitation, by the provision of education for healthcare professionals. Further information on the work of the UKBCG is communicated via this website on a regular basis <https://ukbcg.org/>. Registered charity no: 1177296



This work uses data that have been provided by patients and collected by the NHS as part of their care and support. For patients diagnosed in England, the data are collated, maintained and quality assured by the National Disease Registration Service (NDRS), which is part of NHS England. Access to the data was facilitated by the NHS England Data Access Request Service.



NHS Wales recently implemented Cancer Dataset Forms with the latest implementation date being January 2025. These have been designed to improve the data capture and reporting capabilities of NHS Wales. This implementation has impacted the data quality within NHS Wales.

Contents

1. Introduction.....	2
2. Sources of Data.....	3
3. Inclusion and Exclusion Criteria.....	3
4. Key Data Items.....	5
5. Indicator Definitions.....	6
Performance Indicator 1: Discussed in a multidisciplinary team (MDT)	6
Performance Indicator 2: Biopsy in people with recurrent disease	7
Performance Indicator 3: Receipt of CDK4/6 inhibitors.....	7
Performance Indicator 4: Receipt of anti-HER2 therapy.....	8
Performance Indicator 5: Chemotherapy.....	9
Performance Indicator 6: Receipt of a bisphosphonate or denosumab.....	11
Performance Indicator 7: Radiotherapy.....	11
Performance Indicator 8: Clinical nurse specialist (CNS) contact.....	11
Performance Indicator 9: Death recorded within 30 days of a chemotherapy cycle.....	11
Performance Indicator 10: 1 and 3 year survival.....	12
6. NHS organisations	13
7. Statistical Analysis	14
7.1 1- and 3-year overall survival.....	14
7.2 Suppression.....	14
7.3 Risk-adjustment of indicators	14
7.4 Handling of missing data.....	15
8. Outlier Process	15
Appendix 1: Routine data sources.....	16
Appendix 2: Charlson co-morbidity score	17
Appendix 3: Secondary Care Administrative Records Frailty (SCARF) Index.....	18

1. Introduction

This document provides supporting material to the 2026 State of the Nation (SotN) Report for the National Audit of Metastatic Breast Cancer (NAoMe) and its data tables and data viewer. The document describes the data used in the report with details on sources of data, criteria for inclusion and how data completeness, patient characteristics and performance indicators are derived and reported.

2. Sources of Data

The audit uses information from routine national health care datasets in England and Wales. These datasets capture details on the diagnosis, management, treatment and outcome of every patient newly diagnosed with cancer in the NHS in England and Wales.

For England, the audit received information from the National Disease Registration Service (NDRS) at a tumour level for this State of the Nation report. The information held in the National Cancer Registration Data (NCRD) is compiled from a variety of sources including the Cancer Outcomes and Services Dataset (COSD), Hospital Episode Statistics admitted patient care (HES APC) records, the Systemic Anti-Cancer Therapy dataset (SACT), the Radiotherapy dataset (RTDS) and data submitted by pathology laboratories. The audit also received linked information from COSD (linked at tumour level), HES APC, HES Outpatients data (HES OP), SACT, RTDS and the Primary Care Prescription Database (PCPD) (all linked at patient level). **Appendix 1** provides more detail on the data sources listed below and the information they contain.

The English data received by the National Cancer Audit Collaborating Centre (NATCAN) included data on people registered with cancer from 01 January 2015 up to 31 December 2023.

As with cancer registries in other countries, cancer registrations in England can take up to 5 years after the end of a given calendar year to approach 100% completeness and stability. NDRS uses an active system of gathering information on cancer diagnoses from multiple sources across the patient pathway. Completeness varies by tumour type because different patient pathways provide different opportunities for data flows into NDRS. The 'Gold standard' cancer registration dataset that is used in cancer statistics bulletins and available for analysis outside of NDRS contains over 98% of all the people that will eventually be found by the registration process, and the completeness for a calendar year of data increases over time. More information about the cancer registration process can be found [here](#).

For Wales, the audit was provided with a registration dataset at patient level for people diagnosed with cancer from 01 January 2015 up to 31 December 2023. Welsh cancer registration data is captured through the Cancer Network Information System Cymru (CaNISC) and the new system: Cancer Dataset Forms (CDF). The audit also received linked datasets of records from the Patient Episode Database for Wales (PEDW) containing information on inpatient and day case activity, and mortality data from the Office for National Statistics (ONS). Data from England and Wales were harmonised and analysed together, where available.

3. Inclusion and Exclusion Criteria

The data received for England and Wales is checked and filtered for eligible participants, tables 3.1 and 3.2 explain the process in defining the final cohort to be used in the audit. The NAOme aspires to include all people diagnosed with metastatic breast cancer defined as spread beyond the breast and regional lymph nodes. There are two distinct cohorts of people with metastatic breast cancer identified within the NAOme (Table 3.1):

- 1) *De novo* cohort – metastatic disease identified at diagnosis.
- 2) Recurrent cohort – metastatic disease identified following initial treatments for primary breast cancer.

Currently, information regarding the date and type of recurrent disease is largely missing in both English and Welsh cancer datasets. The methodology outlined in Table 3.1 is being used as an interim solution. This approach does not identify all people with recurrent metastatic breast cancer. In particular, those who did not have a record in the HES-APC dataset are not identified as having recurrence. HES APC includes "any secondary-care based activity that requires a hospital bed, thus including both emergency and planned admission, day cases, births and associated

deliveries. HES APC does not cover accident and emergency (A&E, emergency department) attendances or outpatient bookings; these data are held in separate HES databases.”¹

People were included for analysis within the SotN Report based on the following inclusion and exclusion criteria:

Table 3.1: Audit Inclusion Criteria	
Inclusion Criteria	Details
Type of cancer	A primary diagnosis with ICD-10 diagnosis codes: C50 (invasive breast cancer) or D05 (stage 0)
Adults	Age ≥18
Valid Diagnosis Date	De novo cohort: Primary breast cancer diagnosed 01 January 2021 to 31 December 2023 Recurrent cohort: Primary breast cancer diagnosed 01 January 2015 to 30 June 2023. Recurrence identified between 01 January 2021 to 31 December 2023
Cancer Stage	De novo cohort: Stage 4 at diagnosis according to Cancer Registration/COSD for England or CaNISCC or CDF for Wales OR Stage 0-3 or unknown staging at initial diagnosis with metastatic disease recorded at a distant site in HES-APC or PEDW (ICD10: C78, C79) within 6 months of date of diagnosis Recurrent cohort: Stage 0-3 or unknown staging at initial diagnosis AND secondary malignancy recorded at a distant site in HES-APC or PEDW (ICD10: C78, 79) more than 6 months after date of diagnosis (with admission date between 01 January 2021 and 31 December 2023)

Table 3.2: Audit Exclusion Criteria	
Exclusion Criteria	Details
Reported by death certificate only or date of diagnosis corresponds to date of death	For English data: Using NCRD: basisofdiagnosis = 0 (Death certificate) and/or dco = Y (tumour registered from a death certificate only) and/or date_diagnosis=ONS_date_death For Welsh data: Date_diagnosis = ONS_date_death and/or basisofdiagnosis=0
Diagnosed outside of an eligible NHS organisation in England or Wales.	Diagnosed outside of an NHS organisation in England or Wales OR Diagnosed at an NHS organisation with no active breast unit OR Diagnosed within an NHS organisation with less than 30 allocated registrations of breast cancer per year OR Diagnosed at a tertiary centre Summary level national figures do include people with no place of diagnosis. However, people are excluded from indicators and data completeness if no place of diagnosis is recorded as it is not clear where they would be placed.
Multiple cancer registrations during the audit period	>1 tumour ID in the cancer registration dataset (e.g. bilateral cancer)

¹ <https://pmc.ncbi.nlm.nih.gov/articles/PMC5837677/>

4. Key Data Items

Details of the variables and datasets used to compile the data completeness information are shown below in Table 4.1. Data completeness is reported for only the *de novo* cohort of patients.

Table 4.1: Data Completeness Variables for the <i>de novo</i> cohort				
Data Item	Source			
	England		Wales	
	Data field	Dataset	Data field	Dataset
Clinical Nurse Specialist	CR2050	COSD	CNS_Nurse Seen HasSeenClinicalNurseSpecialist	CaNISC CDF
ER status ^A	ER_STATUS; ER_SCORE / pBR4220	NCRD /COSD	ErStatus ErStatus, ErAllredScore	CaNISC CDF
HER2 status	HER2_STATUS; pBR4280	NCRD/COSD	Her2Status; Her2FishStatus Her2Status, Her2IshStatus	CaNISC CDF
PR status	PR_STATUS; PR_SCORE / pBR4290	NCRD/COSD	PrStatus PrStatus, PrAllredScore	CaNISC CDF
Stage (overall)	STAGE_BEST, T-stage, N- stage, M-stage	NCRD	StageGroupIntegrated StageGroupFinalPreTreatment	CaNISC CDF
T-stage	T_BEST	NCRD	FirstGradeOfDifferentiationPathology TStageFinalPreTreatment	CaNISC CDF
N-stage	N_BEST	NCRD	FirstNumberOfNodesExamined FirstNumberOfNodesPositive NStageFinalPreTreatment	CaNISC CDF
Grade	GRADE	NCRD	FirstGradeOfDifferentiationPathology GradeOfDifferentiationDiagnosis	CaNISC CDF

^A The percentage reported for data completeness reflects the data quality as received by the NAOpri, without augmentation with data for endocrine therapy prescription, to highlight the need for improved data quality. When oestrogen receptor status was used for risk adjustment or for subgroup analyses, this was augmented with data from Primary Care Prescription Database, where persons receiving endocrine therapy were assumed to be ER-positive.

Details of the variables and datasets used to compile the patient and tumour characteristics for each cohort are shown below in Tables 4.2 and 4.3.

Table 4.2: Patient and Tumour Characteristics Variables for the <i>de novo</i> cohort				
Data Item	Source			
	England		Wales	
	Data field	Dataset	Data field	Dataset
Year of Diagnosis	DIAGNOSISDATEBEST / CR2030	NCRD/COSD	DateOfPrimaryDiagnosis DateOfPrimaryDiagnosis	CaNISC CDF
Age at diagnosis	Birthmonth; birthyear / CR0100	NCRD/COSD	AgeAtDiagnosis Age at Diagnosis	CaNISC CDF
Sex	SEX	NCRD	Gender Gender	CaNISC CDF
Screened	SCREEN_DETECTED / CR1600	NCRD/COSD	CancerReferralSource CancerReferralSource	CaNISC CDF
Ethnic Group	ETHNICITY / CR0150	NCRD/COSD	N/A PatientEthnicGroupDescription	CaNISC CDF
Index of Multiple Deprivation Quintile	QUINTILE_2019 / CR0080	NCRD/COSD	LSOA_ Deprivation Quintile Group DeprivationQuintile	CaNISC CDF
SCARF index	DIAG_nn	HES APC	Diagnosis_n	PEDW
Charlson comorbidity score	DIAG_nn	HES APC	Diagnosis_n	PEDW
Metastatic disease	DIAG_nn	HES APC	Diagnosis_n	PEDW

Stage (overall)	STAGE_BEST, T-stage N-Stage, M-stage (from M_Best) SITE_ICD10	NCRD	StageGroupIntegrated StageGroupFinalPreTreatment and DiagnosisICD10	CaNISC CDF
Date of Death	Vitalstatus, vitalstatusdate, deathdatebest	NCRS/ONS	DeathDate	ONS

Table 4.3: Patient and Tumour Characteristics Variables for the recurrent cohort

<u>Data Item</u>	<u>Source</u>			
	England		Wales	
	<u>Data field</u>	<u>Dataset</u>	<u>Data field</u>	<u>Dataset</u>
Date of recurrence	Date of first ICD-10 code for metastatic breast cancer (DIAG_nn)	HES APC	Date of first ICD-10 code for metastatic breast cancer.	PEDW
Age at first metastases recorded	Birthmonth; birthyear / CR0100 & Date of recurrence	NCRD/COSD	AgeAtDiagnosis (first diagnosis), DateofDiagnosis (first diagnosis) & Date of recurrence	CaNISC/CDF
Sex	SEX	NCRD	Gender	CaNISC/CDF
Ethnic Group	ETHNICITY / CR0150	NCRD/COSD	N/A PatientEthnicGroupDescription	CaNISC CDF
Site of metastases	DIAG_nn	HES APC	Diagnosis_n	PEDW

5. Indicator Definitions

The audit uses key indicators to monitor progress against its healthcare improvement goals. These indicators align with national guidelines and standards. Definitions of how the indicators included in the SotN report were derived from data for England and Wales are described below.

Some indicators are focused on subgroups of patients as defined histopathology or treatment, as these factors are important determinants of whether particular treatments or processes are suitable for patients.

Performance Indicator 1: Discussed in a multidisciplinary team (MDT)

Percentage of people with newly diagnosed metastatic breast cancer (MBC) (*de novo*) disease who have their care discussed within a multidisciplinary team (MDT) meeting.

Table 5.1: Percentage of people with newly diagnosed metastatic breast cancer (MBC) discussed in a multidisciplinary team (MDT).

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	1/1/2021 to 31/12/2023
Numerator: Number of people who were discussed at an MDT.	COSD_date_firstmdtmeeting1 is completed.	Non missing value for CancerCarePlanMDTDate
Denominator: Number of people with invasive breast cancer and evidence of <i>de novo</i> metastatic disease.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.
Construction notes	Recorded MDT date is within 30 days of date of diagnosis.	Recorded MDT date is within 30 days of date of diagnosis.
Country reporting:	England & Wales – combined and separate.	

Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the decision to treat, as recorded in the Cancer Waiting Times dataset.	Welsh Health Boards
Subgroup Reporting:	Gender, age-group and diagnosis year.	Gender, age-group and diagnosis year.
Risk adjusted:	No – not required as should be near 100% regardless of case-mix.	
Outlier reporting:	No	

Performance Indicator 2: Biopsy in people with recurrent disease

Percentage of people with recurrent metastatic breast cancer who had a biopsy to inform care.

This performance indicator is reported for England only due to differences in data availability. There is an absence of treatment data available for the recurrent cohort for Wales, precluding any reporting.

Table 5.2: Percentage of people with recurrent metastatic breast cancer who had a lesion biopsied to inform care.

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available
Numerator: Number of people who have a lesion biopsied.	Biopsy in COSD no more than 6 months prior to, or any time after recurrence ^A and at least six months after initial diagnosis	Not available
Denominator: Number of people with invasive breast cancer and evidence of recurrent metastatic disease.	Final recurrent cohort as described in section 3, inclusion and exclusion criteria.	Not available
Construction notes	Date for biopsy or fine needle aspiration cytology in COSD-pathology file: no more than six months before date of recurrence and at least six months after the date of primary diagnosis and at any time after recurrence ^A .	Not available
Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People are allocated to the trust that recorded their metastases in HES-APC.	Not available
Subgroup Reporting:	Gender, age-group and diagnosis year.	Not available
Risk adjusted:	No	
Outlier reporting:	No	

^A A wide time interval is used to account for the fact that date of recurrence from HES is not likely to be the true date a recurrence was discovered.

Performance Indicator 3: Receipt of CDK4/6 inhibitors.

Percentage of people with ER positive MBC who received CDK4/6 inhibitors.

This performance indicator is reported for England only due to differences in data availability. There is an absence of data for CDK4/6 inhibitors for Wales, precluding reporting.

Table 5.3: Percentage of people with ER positive MBC who received CDK4/6 inhibitors.

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available

Numerator: Number of people who have treatment with a CDK4/6 inhibitor initiated.	Record of CDK4/6 inhibitor within SACT dataset.	Not available
Denominator: Number of people with ER positive, HER2 negative or HER2 "unknown", invasive breast cancer with evidence of <i>de novo</i> metastatic disease (excluding those who die within 30 days of diagnosis).	Final <i>de novo cohort</i> as described in section 3, inclusion and exclusion criteria. Restricted to those with ER positive, HER2 negative or HER2 unknown disease. Excluding those who die within 30 days of diagnosis.	Not available
Construction notes	If SACT drug name is one of abemaciclib, palbociclib, ribociclib, and using matching date_SACT_administration	Not available
Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the decision to treat, as recorded in the Cancer Waiting Times dataset.	Not available
Subgroup Reporting:	Gender, age-group and diagnosis year.	Not available
Risk adjusted:	Yes – age, gender, tumour grade, Charlson co-morbidity score, SCARF frailty index, source of metastases and diagnosis year.	
Outlier reporting:	No	

Performance Indicator 4: Receipt of anti-HER2 therapy.

Percentage of people with HER2 positive MBC who received anti-HER2 therapy within six months of diagnosis.

This performance indicator is reported for England only due to differences in data availability. There is an absence of data for dates of administration of anti-HER2 therapy for Wales, precluding reporting.

Table 5.4: Percentage of people with HER2 positive MBC who received anti-HER2 therapy within six months of diagnosis		
	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available
Numerator: Number of people who have treatment with an anti-HER2 therapy initiated.	Record of anti-HER2 therapy within the SACT dataset with an administration date within 6 months of the date of diagnosis.	Not available
Denominator: Number of people with HER2-positive invasive breast cancer and evidence of metastatic disease (excluding those who die within 30 days of diagnosis).	Final <i>de novo cohort</i> as described in section 3, inclusion and exclusion criteria. Restricted to those with HER2 positive disease. Excluding those who die within 30 days of diagnosis.	Not available
Construction notes	If SACT-name is one of the following: Lapatinib (Tykerb, Tyverb), Neratinib (Nerlynx), Pertuzumab (Perjeta), trastuzumab (Herceptin, Herzuma, Ontruzant, Trazimera), Phesgo, Trastuzumab duocarmazine (Syd985), Tucatinib and using matching date_SACT_administration	Not available

Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the decision to treat, as recorded in the Cancer Waiting Times dataset.	Not available
Subgroup Reporting:	Gender, age-group and diagnosis year.	Not available
Risk adjusted:	Yes - age, tumour grade, Charlson co-morbidity score, SCARF frailty index, source of metastases, ER-status and diagnosis year.	
Outlier reporting:	No	

Performance Indicator 5: Chemotherapy.

Percentage of people with *de novo* disease who received any chemotherapy. This indicator is presented for both the *de novo* and recurrent population, separately. Treatment for the recurrent population is not available for Wales. The new CDF datasets for Wales had disrupted data flows for chemotherapy and the rates in Wales therefore appear lower in 2023.

Table 5.5: Percentage of people with <i>de novo</i> MBC who received chemotherapy.		
	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	1/1/2021 to 31/12/2023
Numerator: Number of people who have treatment with chemotherapy initiated.	Record of chemotherapy within the SACT dataset.	Record of chemotherapy within the CaNISC, CDF or SACT dataset.
Denominator: Number of people with invasive breast cancer and evidence of <i>de novo</i> metastatic disease.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.
Construction notes	Any record in SACT of administration of one of the following: abemaciclib, alpelisib, capecitabine, carboplatin, cyclophosphamide, datopotamab, deruxtecan, docetaxel, doxorubicin, epirubicin, eribulin, everolimus, fluorouracil, gemcitabine, nab-paclitaxel, neratinib, olaparib, paclitaxel, palbociclib, pembrolizumab, pertuzumab, pertuzumab + trastuzumab, pertuzumab + trastuzumab (phesgo), ribociclib, sacituzumab govitecan, trastuzumab, trastuzumab (herceptin), trastuzumab biosimilar, trastuzumab biosimilar (herzuma), trastuzumab biosimilar (kanjinti), trastuzumab biosimilar (ontruzant), trastuzumab biosimilar (trazimera), trastuzumab biosimilar (zercepac), trastuzumab deruxtecan, trastuzumab emtansine and tucatinib.	
Country reporting:	England & Wales – combined and separate.	
Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the	Welsh Health Boards

	decision to treat, as recorded in the Cancer Waiting Times dataset.	
Subgroup Reporting:	Gender, age-group, hormone receptor status and diagnosis year.	Gender, age-group, hormone receptor status and diagnosis year.
Risk adjusted:	Yes - age, tumour grade, Charlson co-morbidity score, SCARF frailty index, source of metastases, ER-status, HER2 status and diagnosis year.	
Outlier reporting:	No	

Table 5.6: Percentage of people with recurrent MBC who received chemotherapy.

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available
Numerator: Number of people who have treatment with chemotherapy initiated.	Record of chemotherapy within the SACT dataset.	Not available
Denominator: Number of people with invasive breast cancer and evidence of recurrent metastatic disease.	Final recurrent cohort as described in section 3, inclusion and exclusion criteria.	Not available
Construction notes	Any record of a date within SACT occurring after the recurrence date or up to 30 days before, but at least six months after the original date of diagnosis with primary breast cancer, where chemotherapy is one of: Any record in SACT of administration of one of the following: abemaciclib, alpelisib, capecitabine, carboplatin, cyclophosphamide, datopotamab deruxtecan, docetaxel, doxorubicin, epirubicin, eribulin, everolimus, fluorouracil, gemcitabine, nab-paclitaxel, neratinib, olaparib, paclitaxel, palbociclib, pembrolizumab, pertuzumab, pertuzumab + trastuzumab, pertuzumab + trastuzumab (phesgo), ribociclib, sacituzumab govitecan, trastuzumab, trastuzumab (herceptin), trastuzumab biosimilar, trastuzumab biosimilar (herzuma), trastuzumab biosimilar (kanjinti), trastuzumab biosimilar (ontruzant), trastuzumab biosimilar (trazimera), trastuzumab biosimilar (zercepac), trastuzumab deruxtecan, trastuzumab emtansine and tucatinib	Not available
Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People are allocated to the trust that recorded their metastases in HES-APC.	Not available
Subgroup Reporting:	Gender, age-group, hormone receptor status and diagnosis year.	Not available
Risk adjusted:	Yes - age, tumour grade, Charlson co-morbidity score, SCARF frailty index, ER-status, HER2 status and diagnosis year.	
Outlier reporting:	No	

Performance Indicator 6: Receipt of a bisphosphonate or denosumab.

Percentage of people with bone metastases who received a bisphosphonate or denosumab.

This performance indicator remains under development and is not yet reported on.

Performance Indicator 7: Radiotherapy.

Percentage of MBC patients who received radiotherapy.

This performance indicator remains under development and is not yet reported on.

Performance Indicator 8: Clinical nurse specialist (CNS) contact.

Percentage of people with clinical nurse specialist (CNS) contact recorded as "Yes".

Table 5.7: Percentage of people with clinical nurse specialist (CNS) contact recorded as "Yes".		
	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	1/1/2021 to 31/12/2023
Numerator: Number of people who have contact with a breast CNS.	Number of people who have COSD data item CR2050 (<i>Clinical Nurse Specialist Indication Code</i>) recorded as yes.	Number of people who have CaNISC data item CNS_Nurse Seen or CDF data item HasSeenClinicalNurseSpecialist recorded as yes.
Denominator: Number of people with invasive breast cancer and evidence of <i>de novo</i> metastatic disease.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.
Construction notes		
Country reporting:	England & Wales – combined and separate.	
Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the decision to treat, as recorded in the Cancer Waiting Times dataset.	Welsh Health Boards
Subgroup Reporting:	Gender, age-group and diagnosis year.	Gender, age-group and diagnosis year.
Risk adjusted:	No – not required as we expect this to be yes, regardless of case-mix.	
Outlier reporting:	No	

Performance Indicator 9: Death recorded within 30 days of a chemotherapy cycle.

Percentage of people with death recorded within 30 days of a chemotherapy cycle.. This indicator is presented for both the *de novo* and recurrent population, separately. This metric is not available for Wales as only the first course of chemotherapy was available.

Table 5.8: Percentage of people with <i>de novo</i> metastatic breast cancer with death recorded within 30 days of a chemotherapy cycle.		
	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available
Numerator: Number of people who die within 30 days of a chemotherapy cycle.	Record of mortality up to 30 days after chemotherapy recorded in SACT.	Not available

Denominator: Number of people with invasive breast cancer and evidence of <i>de novo</i> metastatic disease who have received chemotherapy.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria, restricted to those who have had any record of chemotherapy as described in indicator 5.	Not available
Construction notes	Record of date of death within 30 days of last date recorded in SACT dataset.	Not available
Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People were allocated to trusts based on the organisation responsible for the decision to treat, as recorded in the Cancer Waiting Times dataset.	Not available
Subgroup Reporting:	Age-group, gender and diagnosis year	Not available
Risk adjusted:	Yes - age, tumour grade, Charlson co-morbidity score, SCARF frailty index, source of metastases, ER-status, HER2 status and diagnosis year.	Not available
Outlier reporting:	No	

Table 5.9: Percentage of people with recurrent metastatic breast cancer with death recorded within 30 days of a chemotherapy cycle.

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	Not available
Numerator: Number of people who die within 30 days of a chemotherapy cycle.	Record of mortality up to 30 days after chemotherapy recorded in SACT.	Not available
Denominator: Number of people with invasive breast cancer and evidence of recurrent metastatic disease who have received chemotherapy.	Final recurrent cohort as described in section 3, inclusion and exclusion criteria. Restricted to people who have had any record of chemotherapy as described in indicator 5.	Not available
Construction notes:	Record of date of death within 30 days of last date recorded in SACT dataset, where that date occurs after the date of recurrence as described in indicator 5.	Not available
Country reporting:	England only	
Organisational Reporting level:	English NHS Trusts. People are allocated to the trust that recorded their metastases in HES-APC.	Not available
Subgroup Reporting:	Age-group, gender and diagnosis year.	Not available
Risk adjusted:	Yes - age, tumour grade, SCARF frailty index, ER-status, HER2 status and diagnosis year.	Not available
Outlier reporting:	No	

Performance Indicator 10: 1 and 3 year survival.

Percentage of people who survived at least 1 or 3 after diagnosis. Mortality data for England and Wales is derived from Office for National Statistics mortality data.

Table 5.10: Percentage of people who survived at least 1 or 3 years from their initial breast cancer diagnosis.

	<u>England</u>	<u>Wales</u>
Dates of diagnosis:	1/1/2021 to 31/12/2023	1/1/2021 to 31/12/2023
Numerator:	Number of people who survive for at least 1 or 3 years from the date of diagnosis.	Number of people who survive for at least 1 or 3 years from the date of diagnosis.
Denominator: Number of people with invasive breast cancer and evidence of <i>de novo</i> metastatic disease.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.	Final <i>de novo</i> cohort as described in section 3, inclusion and exclusion criteria.
Construction notes:	Used Kaplan-Meier to estimate overall survival. See Statistics section for more information.	
Country reporting:	England & Wales – combined and separate.	
Organisational Reporting level:	National	National
Subgroup Reporting:	Females, ER- and HER2-status	Females, ER- and HER2-status
Risk adjusted:	N/A – reported at the national level	
Outlier reporting:	No	

6. NHS organisations

The audit presents organisation-level findings by the NHS organisation of diagnosis. This is because this is the organisation where diagnosis and multidisciplinary team decisions are likely to be made.

There are some tertiary centres that mainly provide oncological treatment for people with breast cancer. This includes the Christie NHS Foundation Trust, Clatterbridge Cancer Centre NHS Foundation Trust, and Velindre NHS Trust. These tertiary centres are not included directly within audit outputs where findings are reported by the diagnosing NHS organisation. This is because people are not diagnosed at these centres.

This audit assigns people in England to trusts by two different methods:

- Trust responsible for the decision to treat,
- Trust of recurrence

Trust assigned as “diagnosis trust” (not used in NAOme audit): NDRS provides the trust of diagnosis for each person based on the trust where pathology-based diagnosis is made.

Trust responsible for the decision to treat: Where some trusts provide screening and follow-up services to other trusts, this results in the diagnosis being made at the screening trust and people are therefore assigned to the trust of screening rather than trusts that are responsible for their care. We therefore identified the trust responsible for the decision to treat where available which resolves many issues of trust assignment due to screening.

The trust responsible for the decision to treat was identified from the Cancer Waiting Times dataset using `org_dec_to_treat` variable. Records were eligible where the cancer site code was C50 or D05 and the recorded date fell between 90 days before and 365 days after the date of diagnosis. Where this was missing, `org_treat_start` was used as a surrogate. For the small minority of patients for whom both variables were missing, the trust of diagnosis provided by NDRS was used to retain these patients in the analysis.

Trust of recurrence: Where people are identified with recurrence this may be years after their first diagnosis and we therefore use the trust provided in HES-APC where metastases were first identified, where available and trust of first cancer waiting time otherwise.

7. Statistical Analysis

All statistical analyses were conducted using *Stata* version 17.

Most results in the SotN Report are descriptive. The results of categorical data items are reported as percentages (%). Results are typically provided as an overall figure and broken down by NHS organisation of diagnosis (see NHS organisations section). Note that within tables in the SotN Report, the total percentage may not equal 100%, due to rounding.

7.1 1- and 3-year overall survival

Overall survival was calculated within *Stata* using Kaplan-Meier survival analysis methods. 1- and 3-year overall survival was calculated from the date of breast cancer diagnosis using ONS mortality data. For those people with no ONS date of death, a “date last known alive” or censoring date was calculated for use in survival analyses. For English patients provided by the NCRAS, this was taken to be the vital status date provided; where this date was missing, the day after the last reported date of death was used. For Welsh patients, the day after the last reported date of death was used.

7.2 Suppression

Data suppression is primarily used to protect patient privacy by preventing the disclosure of sensitive information when dealing with small sample sizes or specific combinations of data points. It involves withholding certain data elements to minimize the risk of identifying individuals. For data quality and completeness, disclosure risk is deemed negligible, and results have not been suppressed. For performance indicators, organisations with indicator denominator values of less than 10 have suppressed. Because small numbers are unstable and may lead to spurious conclusions if not provided within context and with appropriate uncertainties, risk-adjusted percentages for indicators with fewer than 10 in the denominator have also been suppressed.

To avoid residual disclosure which could occur by summing across subcategories, where only a single trust within a cancer alliance has been suppressed, a second trust has had the number and unadjusted percentage suppressed to prevent residual disclosure however the risk adjusted percentage is provided.

In the patient characteristics table, for categories with small numbers (1-4) the number has been suppressed by converting it to 2 and editing the numbers of a larger group to maintain the overall total. Therefore, the percentage provided for <5 is similar to the real value and the other numbers in the indicator group may contain a small amount of ‘jitter’. Where the category value is ‘Unknown’, ‘Not in HESAPC’, ‘Not in PEDW’ or ‘Not Recorded’, i.e. it represents missing data, we have not suppressed small numbers.

7.3 Risk-adjustment of indicators

Multivariable logistic regression was performed to ‘risk adjust’ relevant indicators. The regression model is used to estimate the probability of a patient having an outcome (e.g., a given treatment) given patient and tumour characteristics. When summed, these individual probabilities produce the expected number of events at an organisation. The adjusted indicator value for an organisation is then calculated as: the observed number of events at an institution divided by the expected number (based on the national model), multiplied by the overall national average. This is called indirect standardisation. The tables of performance indicators state whether risk adjustment has been performed. Table 7.1 provides details on the datasets and variables used for risk adjustment.

Table 7.1: Risk Adjustment Variables		
Data Item	Additional detail	
	England	Wales

Age at diagnosis	Age, included as a spline (birthmonth; birthyear from NCRD, date of diagnosis from NCRD) For the recurrent cohort also Date of recurrence	Age, included as a spline (AgeAtDiagnosis from CaNISC or Age at Diagnosis from CDF) For the recurrent cohort, AgeAtDiagnosis (first diagnosis), DateofDiagnosis (first diagnosis) & Date of recurrence
Grade	GRADE from NCRD	FirstGradeOfDifferentiationPathology from CaNISC GradeOfDifferentiationDiagnosis from CDF
Charlson co-morbidity score	The Charlson co-morbidity score is a commonly used scoring system for medical comorbidities, consisting of a grouped score calculated based on the absence (0) and presence (≥ 1) of 14 pre-specified medical conditions (Appendix 2). The score was calculated using information on secondary diagnoses (ICD-10 codes) recorded in HES APC (England) / PEDW (Wales) within the 24-month period prior to a person's diagnosis. For analysis, the CCI is grouped into three categories: • 0 none of the 14 pre-specified comorbidities. • 1 only 1 of the 14 pre-specified comorbidities. • 2+ 2 or more of the 14 pre-specified comorbidities	
SCARF Index ^B	Using DIAG_01-DIAG20 from HES APC	Using Diagnosis01-12 from PEDW
Diagnosis year	Year extracted from diagnosisdatebest (NCRD)	Year extracted from DATE OF DIAGNOSIS (CaNISC) or DateOfPrimaryDiagnosis (CDF)
ER Status (Invasive only)	Using ER_STATUS; ER_SCORE from NCRD supplemented with Primary Care Prescription Database Prescriptions dataset to identify people with ER positive breast cancer. See Footnote of Table 4.1	Using ERStatus from CaNISC and ErStatus and ErAllredScore from CDF
HER2 Status (Invasive only)	Using HER2_STATUS from NCRD	Using Her2Status and Her2FishStatus from CaNISC and Her2Status and Her2IshStatus from CDF.
Source of Metastases	Whether metastasis was identified via stage 4 in NCRD or HES (Applicable to <i>de novo</i> cohort only)	Whether metastasis was identified via stage 4 in CaNISC/CDF or HES (Applicable to <i>de novo</i> cohort only)

7.4 Handling of missing data

For the risk-adjustment, multiple imputation techniques are used to allow us to make fair comparisons between hospitals without excluding people with incomplete records. Specifically, missing values within the risk adjustment model were imputed with multiple imputation using chained equations, creating ten datasets and pooling model estimates using Rubin's Rules. The imputation models included all the variables in the risk adjustment model.

8. Outlier Process

The NAOme will not be implementing an outlier process for the findings of this report due to two key limitations: a) the *de novo* population is too small when indicators are produced at a trust level and b) the recurrent population is incomplete, and we do not have information to know how representative this sample is.

Appendix 1: Routine data sources

Overview of the data sources used for the SotN Report.

Country	Data source	Content
England	Cancer registry (NCRD and RCRD)	Data on all aspects of the cancer registration including information from hospital pathology systems.
England	COSD	Cancer Outcomes and Services dataset (COSD) items, are submitted routinely by service providers via multidisciplinary team (MDT) electronic data collection systems to the National Cancer Data Repository (NCDR) on a monthly basis.
England	SACT	Systemic Anti-Cancer Therapy (SACT) data contains information on chemotherapy dates, regimen(s) and dose(s).
England	RTDS	Radiotherapy dataset (RTDS) contains information on radiotherapy treatment including dates, prescription region and dose.
England	HES	Hospital Episode Statistics (HES) is the administrative database of all NHS hospital admissions in England; records were supplied by NHS Digital to NCRAS.
England	PCPD	Primary Care Prescription Database (PCPD) contains information on the use of endocrine therapy.
Wales	CaNISC	Cancer Network Information System Cymru (Canisc) contains data on all aspects of the cancer registration including investigations. (OLD SYSTEM)
Wales	CDF	Cancer Dataset Form (CDF) contains data on all aspects of the cancer registration including investigations (NEW SYSTEM)
Wales	PEDW	Patient Episode Database for Wales (PEDW) is the administrative database of all NHS hospital admissions in Wales.
Wales	RTH	Radiotherapy data (RTH) contains information on radiotherapy treatment.
Wales	SACT	SEW SACT data contains information on chemotherapy treatment.
England & Wales	ONS	Office for National Statistics (ONS) death data including date of death and cause of death.

Appendix 2: Charlson co-morbidity score

Reference:

Armitage JN, van der Meulen JH. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. *Br J Surg* 2010;97:772-81. doi <https://doi.org/10.1002/bjs.6930>

Pre-specified conditions included in the assignment of Charlson co-morbidity score.

Charlson co-morbidity score Conditions
Myocardial infarction
Dementia
Diabetes mellitus
Metastatic solid tumour
Congestive cardiac failure
Chronic pulmonary disease
Hemiplegia or paraplegia
AIDS/HIV infection
Peripheral vascular disease
Rheumatological disease
Renal disease
Cerebrovascular disease
Liver disease
Any malignancy

Note: AIDS/HIV diagnoses cannot be identified in HES APC data because of legal requirements for NHS trusts to remove patient identifiers from legally restricted records, including those containing diagnoses of HIV/AIDS. These diagnoses are also not found in linked PEDW data.

Appendix 3: Secondary Care Administrative Records Frailty (SCARF) Index

Reference:

Jauhari Y, Gannon MR, Dodwell D, et al. Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study. *BMJ Open* 2020;10:e035395. doi: 10.1136/bmjopen-2019-035395

Deficit			
Activity limitation	Diabetic complications	Hypotension	Requirement for care
Anaemia	Falls	Ischaemic heart disease	Respiratory disease
Arthritis	Foot problems	Incontinence	Skin ulcer
Cardiac arrhythmias	Fragility fracture	Neurodegenerative disorders	Sleep disturbance
Cerebrovascular disease	Hearing impairment	Nutritional Problems	Social vulnerability
Chronic kidney disease	Heart failure	Osteoporosis	Thyroid disease
Cognitive and mental health problems	Heart valve disease	Peptic ulcer	Urinary system disease
Diabetes	Hypertension	Peripheral vascular disease	Visual impairment